Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

Fig. 1

Dendritic cell subsets. Dendritic cells can be differentiated from monocytes (moDC), which are often used in clinical trials because of their high yield. The naturally circulating dendritic cells can now also be enriched by immunomagnetic isolation. The naturally circulating dendritic cells can further be divided in myeloid (CD141+ and CD1c+ mDC) and plasmacytoid dendritic cells (pDC). The subsets differ in function, localization, phenotype and cytokine production

Back to article page